Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cell Therapy Potency Assay Summit reveals exclusive insights on regulatory interactions and potency assay development
By Christine Filippis / June 16, 2023
Cartherics’ Acting Chief Scientific Officer, Dr Walid Azar recently attended the 2nd Cell Therapy Potency Assay Summit in Boston. The...
Read More
Global IP takes centre stage at the 21st Advanced Summit on Life Sciences Patents
By Christine Filippis / May 30, 2023
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in...
Read More
Cartherics to present at the 2023 BIO International Convention
By Christine Filippis / May 24, 2023
Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of...
Read More
